CSIMarket Company Name, Ticker, Suppliers, else..


Keros Therapeutics Inc   (NASDAQ: KROS)
Other Ticker:  
 

Keros Therapeutics Inc

KROS's Fundamental analysis



Looking into Keros Therapeutics Inc growth rates, revenue grew by 3602.46 % in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 16

Major Pharmaceutical Preparations industry recorded growth of revenues by 4.43 %

Keros Therapeutics Inc realized net income compared to net loss a year ago in first quarter of 2025

• More on KROS's Growth


Keros Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Keros Therapeutics Inc PEG ratio is at -19.45 Company is currently trading with Price to Cash flow multiple of 2 in trailing twelve-month period.
Company
1947.55
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.32.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.


• More on KROS's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 2,599,946
 Net Income/Employee (TTM) $ 45,783
 Receivable Turnover (TTM) 46.84
 Tangible Book Value (Per Share $) 17.77

Keros Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Keros Therapeutics Inc PEG ratio is at -19.45 Company is currently trading with Price to Cash flow multiple of 2 in trailing twelve-month period.
Company
1947.55
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.32.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.

Keros Therapeutics Inc Price to Book Ratio is at 0.76 lower than Industry Avg. of 33.92. and higher than S&P 500 Avg. of 0.01

• More on KROS's Valuation

•  Market Capitalization (Millions $) 556
•  Shares Outstanding (Millions) 41
•  Employees 92
•  Revenues (TTM) (Millions $) 239
•  Net Income (TTM) (Millions $) 4
•  Cash Flow (TTM) (Millions $) 278
•  Capital Exp. (TTM) (Millions $) -2
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 2,599,946
•  Net Income/Employee(TTM) $ 45,783
•  Receivable Turnover Ratio (TTM) 46.84
•  Tangible Book Value (Per Share $) 17.77

•  Market Capitalization (Millions $) 556
•  Shares Outstanding (Millions) 41
•  Employees 92
•  Revenues (TTM) (Millions $) 239
•  Net Income (TTM) (Millions $) 4
•  Cash Flow (TTM) (Millions $) 278
•  Capital Exp. (TTM) (Millions $) -2


    KROS's Profitability Comparisons
Keros Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 69.73 %.

Keros Therapeutics Inc net profit margin of 68.08 % is currently ranking no. 8 in Major Pharmaceutical Preparations industry, ranking no. 16 in Healthcare sector and number 86 in S&P 500.


Profitability by Segment
Total 68.08 %



  Ratio
•   Capital Ratio (MRQ) 19.29
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.08
•  Asset Turnover Ratio (TTM) 0.39
•  Inventory Turnover Ratio (TTM) -



Keros Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 69.73 %.

Keros Therapeutics Inc net profit margin of 68.08 % is currently ranking no. 8 in Major Pharmaceutical Preparations industry, ranking no. 16 in Healthcare sector and number 86 in S&P 500.

• More on KROS's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com